Andrew Curtis — Head - Corporate Strategy & Business Development at Affimed N.V.

Mr. Andrew D. Curtis has been Head of Corporate Strategy and Business Development at Affimed N.V. since December 2, 2015. Mr. Curtis served as the Chief Executive Officer and President of Jerini US, Inc., a subsidiary of Jerini AG. As a Member of the Jerini AG senior management team, Mr. Curtis built and led the U.S. commercial team - including Medical, Scientific Affairs, Marketing, Distribution and Reimbursement - in preparation for approval and launch of an Orphan Drug treatment for a rare genetic disease. He served as Vice President for U.S. Marketing at Jerini US, Inc. since May 1, 2006. He headed Jerini's established subsidiary, Jerini U.S., Inc., headquartered in the New York metropolitan area. He has more than 20 years of pharmaceutical experience. He initially joined Pfizer in 2003 as U.S. Diversified Senior Product Manager and was later named Director of Marketing for Aricept. He lead Pfizer's Specialty Care Business Unit's External Opportunities and New Business team. Specifically, his team explores novel white space strategies and provides commercial and strategic business development guidance to key SCBU stakeholders. Previously, he led the Biotherapeutic's Business Innovation and Strategy team, focusing on a novel Open Innovation model for Pfizer's BioTherapeutics R&D organization. He served as Global Team Lead for the Biosimilars and Orphan Drugs division within Pfizer's Established Products Business Unit. He began his pharmaceutical career at Aventis and held marketing and sales positions at Merck, Genzyme, TargetRx and J&J. In his previous positions, he successfully managed product filings and launches and gained expertise in the areas of orphan drugs and rare genetic diseases, metabolic bone disease, burn treatment and vaccine therapy. He serves as a Director of The Alpha-1 Project, Inc. Mr. Curtis holds a B.A. from Muhlenberg College and a M.A. from Lehigh University.